 Rasika Mathias
Concepts (799)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 93 | 2026 | 1406 | 5.220 |
Why?
| | Polymorphism, Single Nucleotide | 105 | 2026 | 2145 | 4.590 |
Why?
| | Genetic Predisposition to Disease | 71 | 2026 | 2363 | 4.080 |
Why?
| | Peanut Hypersensitivity | 7 | 2026 | 143 | 3.700 |
Why?
| | Asthma | 51 | 2025 | 1767 | 3.580 |
Why?
| | Arachis | 6 | 2026 | 108 | 2.600 |
Why?
| | Whole Genome Sequencing | 28 | 2026 | 182 | 2.320 |
Why?
| | Dermatitis, Atopic | 9 | 2023 | 321 | 2.190 |
Why?
| | Precision Medicine | 22 | 2026 | 457 | 2.100 |
Why?
| | Food Hypersensitivity | 4 | 2023 | 164 | 1.990 |
Why?
| | Genetic Variation | 31 | 2025 | 983 | 1.980 |
Why?
| | Fatty Acid Desaturases | 12 | 2021 | 31 | 1.890 |
Why?
| | Genome, Human | 20 | 2025 | 422 | 1.790 |
Why?
| | Immunoglobulin E | 18 | 2021 | 315 | 1.750 |
Why?
| | Platelet Aggregation | 12 | 2021 | 105 | 1.670 |
Why?
| | Genotype | 42 | 2025 | 1833 | 1.590 |
Why?
| | Induced Pluripotent Stem Cells | 4 | 2021 | 276 | 1.570 |
Why?
| | Allergens | 6 | 2026 | 384 | 1.560 |
Why?
| | Exome | 14 | 2022 | 227 | 1.540 |
Why?
| | Genomics | 18 | 2025 | 834 | 1.480 |
Why?
| | Multifactorial Inheritance | 6 | 2025 | 202 | 1.470 |
Why?
| | Immunoglobulin G | 4 | 2026 | 893 | 1.470 |
Why?
| | Blood Platelets | 12 | 2022 | 400 | 1.400 |
Why?
| | Kaposi Varicelliform Eruption | 4 | 2021 | 21 | 1.350 |
Why?
| | Alleles | 22 | 2023 | 879 | 1.340 |
Why?
| | Quantitative Trait Loci | 19 | 2026 | 374 | 1.340 |
Why?
| | Genetics, Population | 16 | 2025 | 214 | 1.290 |
Why?
| | Megakaryocytes | 3 | 2021 | 34 | 1.220 |
Why?
| | Phenotype | 51 | 2025 | 3162 | 1.190 |
Why?
| | Humans | 250 | 2026 | 144759 | 1.160 |
Why?
| | Genetic Loci | 18 | 2021 | 261 | 1.150 |
Why?
| | Fatty Acids, Omega-6 | 5 | 2017 | 48 | 1.120 |
Why?
| | Nasal Mucosa | 3 | 2025 | 112 | 1.050 |
Why?
| | Multigene Family | 9 | 2021 | 204 | 1.010 |
Why?
| | Coronary Artery Disease | 11 | 2025 | 741 | 0.980 |
Why?
| | Receptors, Cell Surface | 8 | 2024 | 377 | 0.950 |
Why?
| | DNA Methylation | 7 | 2025 | 681 | 0.950 |
Why?
| | Transcriptome | 5 | 2025 | 1045 | 0.940 |
Why?
| | Gene Frequency | 23 | 2024 | 481 | 0.920 |
Why?
| | Gene Expression Regulation | 11 | 2025 | 2608 | 0.910 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 13 | 2026 | 103 | 0.910 |
Why?
| | Linoleic Acid | 6 | 2023 | 44 | 0.860 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2024 | 26 | 0.840 |
Why?
| | Hypersensitivity, Immediate | 2 | 2023 | 40 | 0.810 |
Why?
| | Male | 119 | 2026 | 72315 | 0.780 |
Why?
| | Genetic Linkage | 14 | 2022 | 273 | 0.780 |
Why?
| | Models, Genetic | 14 | 2025 | 536 | 0.780 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2022 | 16 | 0.750 |
Why?
| | Female | 119 | 2026 | 78271 | 0.730 |
Why?
| | Chromosome Mapping | 16 | 2021 | 510 | 0.730 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 11 | 2021 | 920 | 0.710 |
Why?
| | Linkage Disequilibrium | 19 | 2022 | 246 | 0.700 |
Why?
| | 2S Albumins, Plant | 1 | 2022 | 31 | 0.700 |
Why?
| | Gene-Environment Interaction | 4 | 2026 | 180 | 0.700 |
Why?
| | Gene Expression | 4 | 2025 | 1490 | 0.700 |
Why?
| | Mosaicism | 4 | 2025 | 73 | 0.690 |
Why?
| | Antigens, Plant | 1 | 2022 | 55 | 0.690 |
Why?
| | Nucleotide Transport Proteins | 1 | 2021 | 1 | 0.680 |
Why?
| | Frailty | 4 | 2025 | 198 | 0.680 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2019 | 549 | 0.680 |
Why?
| | Middle Aged | 71 | 2026 | 35875 | 0.670 |
Why?
| | von Willebrand Factor | 6 | 2025 | 85 | 0.640 |
Why?
| | Antibody Formation | 1 | 2022 | 294 | 0.640 |
Why?
| | Platelet Function Tests | 3 | 2021 | 34 | 0.630 |
Why?
| | Herpesvirus 1, Human | 1 | 2021 | 84 | 0.620 |
Why?
| | Genetic Association Studies | 13 | 2024 | 372 | 0.620 |
Why?
| | Lung | 10 | 2022 | 4109 | 0.610 |
Why?
| | Lipids | 8 | 2023 | 710 | 0.600 |
Why?
| | Pedigree | 8 | 2025 | 514 | 0.590 |
Why?
| | Adult | 68 | 2025 | 40449 | 0.580 |
Why?
| | Open Reading Frames | 3 | 2021 | 132 | 0.560 |
Why?
| | Fibrinogen | 7 | 2024 | 177 | 0.540 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2026 | 2583 | 0.530 |
Why?
| | Alzheimer Disease | 1 | 2023 | 621 | 0.500 |
Why?
| | Chromosomes, Human, Pair 11 | 5 | 2014 | 58 | 0.490 |
Why?
| | Human Migration | 1 | 2016 | 25 | 0.490 |
Why?
| | Computational Biology | 5 | 2025 | 680 | 0.490 |
Why?
| | Pulmonary Emphysema | 3 | 2014 | 275 | 0.480 |
Why?
| | Case-Control Studies | 21 | 2025 | 3604 | 0.480 |
Why?
| | Risk Factors | 24 | 2025 | 10779 | 0.480 |
Why?
| | Platelet Activation | 4 | 2018 | 104 | 0.470 |
Why?
| | Gene Flow | 1 | 2016 | 85 | 0.470 |
Why?
| | Evolution, Molecular | 3 | 2019 | 514 | 0.440 |
Why?
| | Software | 5 | 2024 | 690 | 0.440 |
Why?
| | Haplotypes | 14 | 2025 | 490 | 0.440 |
Why?
| | Blood Proteins | 3 | 2025 | 249 | 0.420 |
Why?
| | Geography | 2 | 2016 | 203 | 0.420 |
Why?
| | RNA | 1 | 2021 | 940 | 0.410 |
Why?
| | Polymorphism, Genetic | 11 | 2017 | 612 | 0.410 |
Why?
| | Aging | 5 | 2025 | 1966 | 0.410 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 7 | 0.410 |
Why?
| | Fatty Acids, Unsaturated | 4 | 2020 | 98 | 0.400 |
Why?
| | Diet | 4 | 2023 | 1273 | 0.400 |
Why?
| | Desensitization, Immunologic | 2 | 2026 | 89 | 0.400 |
Why?
| | Biomarkers | 8 | 2025 | 4271 | 0.400 |
Why?
| | Bronchial Hyperreactivity | 1 | 2014 | 96 | 0.390 |
Why?
| | Epigenesis, Genetic | 6 | 2024 | 684 | 0.390 |
Why?
| | Quantitative Trait, Heritable | 6 | 2021 | 118 | 0.380 |
Why?
| | Interferon-gamma | 3 | 2015 | 784 | 0.380 |
Why?
| | Hypersensitivity | 4 | 2024 | 252 | 0.370 |
Why?
| | Mutation | 10 | 2026 | 4089 | 0.370 |
Why?
| | Airway Obstruction | 1 | 2014 | 162 | 0.350 |
Why?
| | Child | 30 | 2025 | 22633 | 0.350 |
Why?
| | Immunity, Cellular | 1 | 2013 | 272 | 0.350 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2021 | 142 | 0.350 |
Why?
| | Chromosome Aberrations | 3 | 2026 | 162 | 0.340 |
Why?
| | Leukocytes | 4 | 2023 | 295 | 0.340 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2011 | 66 | 0.330 |
Why?
| | Likelihood Functions | 5 | 2012 | 143 | 0.330 |
Why?
| | Cardiovascular Diseases | 8 | 2025 | 2168 | 0.330 |
Why?
| | United States | 30 | 2026 | 15966 | 0.330 |
Why?
| | Mendelian Randomization Analysis | 3 | 2024 | 55 | 0.330 |
Why?
| | Dyslipidemias | 3 | 2016 | 181 | 0.330 |
Why?
| | Aged | 35 | 2025 | 25913 | 0.320 |
Why?
| | RNA, Long Noncoding | 2 | 2023 | 177 | 0.310 |
Why?
| | Liver | 7 | 2024 | 1887 | 0.310 |
Why?
| | Cell Adhesion Molecules | 2 | 2024 | 178 | 0.310 |
Why?
| | DNA, Mitochondrial | 2 | 2023 | 211 | 0.310 |
Why?
| | Genome | 4 | 2022 | 306 | 0.310 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 1098 | 0.310 |
Why?
| | Factor VIII | 2 | 2024 | 104 | 0.310 |
Why?
| | Cohort Studies | 15 | 2021 | 5960 | 0.310 |
Why?
| | Adolescent | 29 | 2023 | 22428 | 0.300 |
Why?
| | Telomere | 5 | 2024 | 288 | 0.300 |
Why?
| | Organ Specificity | 2 | 2021 | 312 | 0.290 |
Why?
| | Healthcare Disparities | 3 | 2025 | 727 | 0.290 |
Why?
| | Smoking | 6 | 2018 | 1472 | 0.290 |
Why?
| | Computer Simulation | 8 | 2024 | 1025 | 0.290 |
Why?
| | Pharmacogenetics | 2 | 2020 | 172 | 0.280 |
Why?
| | Genetic Pleiotropy | 3 | 2019 | 32 | 0.280 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 570 | 0.280 |
Why?
| | Dietary Fats | 1 | 2010 | 314 | 0.270 |
Why?
| | Germ-Line Mutation | 3 | 2025 | 172 | 0.270 |
Why?
| | HLA-DQ beta-Chains | 2 | 2021 | 57 | 0.270 |
Why?
| | Arachidonic Acid | 6 | 2015 | 101 | 0.270 |
Why?
| | Atherosclerosis | 2 | 2025 | 409 | 0.270 |
Why?
| | Gene Regulatory Networks | 2 | 2024 | 318 | 0.260 |
Why?
| | Point Mutation | 2 | 2025 | 243 | 0.260 |
Why?
| | Fasting | 2 | 2022 | 277 | 0.260 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 917 | 0.250 |
Why?
| | Blood Glucose | 5 | 2026 | 2327 | 0.250 |
Why?
| | Body Height | 4 | 2015 | 202 | 0.250 |
Why?
| | Loss of Function Mutation | 3 | 2021 | 46 | 0.250 |
Why?
| | Restless Legs Syndrome | 1 | 2006 | 20 | 0.250 |
Why?
| | Aspirin | 4 | 2018 | 399 | 0.240 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2006 | 23 | 0.240 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2006 | 64 | 0.240 |
Why?
| | Computer Graphics | 1 | 2006 | 41 | 0.240 |
Why?
| | Schistosoma japonicum | 2 | 2017 | 33 | 0.230 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 56 | 0.230 |
Why?
| | Metabolic Syndrome | 4 | 2025 | 354 | 0.230 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 102 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 758 | 0.230 |
Why?
| | Helminthiasis | 2 | 2017 | 11 | 0.220 |
Why?
| | Serine | 1 | 2006 | 145 | 0.220 |
Why?
| | Health Status Disparities | 3 | 2025 | 321 | 0.220 |
Why?
| | Hematopoietic Stem Cells | 3 | 2024 | 420 | 0.220 |
Why?
| | Endophenotypes | 1 | 2025 | 21 | 0.220 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 13 | 0.220 |
Why?
| | von Willebrand Diseases | 1 | 2025 | 28 | 0.220 |
Why?
| | Hematopoiesis | 2 | 2023 | 194 | 0.220 |
Why?
| | Membrane Proteins | 7 | 2017 | 1166 | 0.220 |
Why?
| | Cholesterol, HDL | 4 | 2016 | 200 | 0.220 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2025 | 33 | 0.220 |
Why?
| | Chromosomes, Human, Y | 1 | 2025 | 36 | 0.220 |
Why?
| | Models, Statistical | 7 | 2021 | 681 | 0.220 |
Why?
| | Consanguinity | 2 | 2005 | 49 | 0.220 |
Why?
| | Child, Preschool | 17 | 2026 | 11787 | 0.210 |
Why?
| | Chromosome Deletion | 1 | 2025 | 124 | 0.210 |
Why?
| | Kininogens | 1 | 2024 | 6 | 0.210 |
Why?
| | Inflammation | 6 | 2024 | 2878 | 0.210 |
Why?
| | Chromosomes, Human, Pair 16 | 3 | 2021 | 35 | 0.210 |
Why?
| | Lectins, C-Type | 1 | 2024 | 62 | 0.210 |
Why?
| | Interleukin-13 | 3 | 2023 | 144 | 0.210 |
Why?
| | Telomere Homeostasis | 1 | 2024 | 33 | 0.210 |
Why?
| | Young Adult | 13 | 2022 | 14105 | 0.210 |
Why?
| | Forced Expiratory Volume | 4 | 2019 | 449 | 0.210 |
Why?
| | Chemokines, CC | 2 | 2014 | 32 | 0.210 |
Why?
| | Blood Pressure | 6 | 2022 | 1769 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2730 | 0.210 |
Why?
| | Liver Cirrhosis | 2 | 2017 | 288 | 0.200 |
Why?
| | Leukemia | 1 | 2026 | 245 | 0.200 |
Why?
| | Population Groups | 3 | 2019 | 58 | 0.200 |
Why?
| | Fibronectins | 1 | 2024 | 136 | 0.200 |
Why?
| | Menopause, Premature | 1 | 2023 | 12 | 0.200 |
Why?
| | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 2 | 2022 | 3 | 0.200 |
Why?
| | Barbados | 8 | 2013 | 8 | 0.200 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 2 | 2017 | 29 | 0.190 |
Why?
| | Administration, Oral | 1 | 2026 | 847 | 0.190 |
Why?
| | Respiration | 2 | 2014 | 206 | 0.190 |
Why?
| | Blood Cells | 1 | 2022 | 37 | 0.190 |
Why?
| | Frameshift Mutation | 1 | 2022 | 32 | 0.190 |
Why?
| | Proteomics | 3 | 2024 | 1195 | 0.190 |
Why?
| | Erythrocytes | 2 | 2021 | 757 | 0.190 |
Why?
| | Interleukin-4 | 2 | 2023 | 206 | 0.190 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2025 | 96 | 0.190 |
Why?
| | Chromosomes, Human, X | 2 | 2021 | 76 | 0.190 |
Why?
| | Telomere Shortening | 1 | 2022 | 19 | 0.180 |
Why?
| | Promoter Regions, Genetic | 6 | 2023 | 1257 | 0.180 |
Why?
| | Eczema | 1 | 2023 | 66 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 358 | 0.180 |
Why?
| | Proteome | 2 | 2024 | 518 | 0.180 |
Why?
| | Nerve Tissue Proteins | 5 | 2022 | 592 | 0.180 |
Why?
| | Acute Coronary Syndrome | 2 | 2016 | 293 | 0.180 |
Why?
| | Gastritis | 1 | 2023 | 115 | 0.180 |
Why?
| | Genetic Heterogeneity | 3 | 2016 | 62 | 0.180 |
Why?
| | Coronary Disease | 2 | 2019 | 383 | 0.180 |
Why?
| | Enteritis | 1 | 2023 | 103 | 0.180 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 35 | 0.180 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 221 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2025 | 1129 | 0.170 |
Why?
| | Dinoprostone | 1 | 2022 | 178 | 0.170 |
Why?
| | Patient Compliance | 1 | 2025 | 588 | 0.170 |
Why?
| | Americas | 1 | 2021 | 26 | 0.170 |
Why?
| | Infant | 10 | 2026 | 10034 | 0.170 |
Why?
| | Spain | 1 | 2021 | 48 | 0.170 |
Why?
| | DNA Copy Number Variations | 2 | 2020 | 183 | 0.170 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2014 | 81 | 0.170 |
Why?
| | Peru | 1 | 2021 | 62 | 0.170 |
Why?
| | Pulmonary Medicine | 2 | 2019 | 79 | 0.170 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2021 | 84 | 0.170 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.170 |
Why?
| | Leishmaniasis, Visceral | 1 | 2001 | 24 | 0.170 |
Why?
| | Odds Ratio | 7 | 2019 | 1075 | 0.170 |
Why?
| | Glutathione Transferase | 1 | 2021 | 100 | 0.170 |
Why?
| | Cytokines | 4 | 2023 | 2061 | 0.170 |
Why?
| | Risk | 7 | 2019 | 911 | 0.160 |
Why?
| | DNA-Binding Proteins | 4 | 2023 | 1499 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2025 | 301 | 0.160 |
Why?
| | gamma-Linolenic Acid | 1 | 2020 | 2 | 0.160 |
Why?
| | Receptors, Nicotinic | 2 | 2013 | 321 | 0.160 |
Why?
| | Chromosomes, Human, Pair 19 | 3 | 2012 | 26 | 0.160 |
Why?
| | HLA-DQ Antigens | 1 | 2021 | 173 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2022 | 255 | 0.160 |
Why?
| | Lipid Metabolism | 2 | 2021 | 527 | 0.160 |
Why?
| | Soybean Oil | 1 | 2020 | 15 | 0.160 |
Why?
| | Plant Oils | 1 | 2020 | 31 | 0.160 |
Why?
| | Algorithms | 7 | 2025 | 1837 | 0.160 |
Why?
| | Energy Intake | 1 | 2023 | 499 | 0.160 |
Why?
| | Amish | 1 | 2020 | 7 | 0.160 |
Why?
| | Base Sequence | 4 | 2021 | 2190 | 0.160 |
Why?
| | beta-Globins | 1 | 2019 | 8 | 0.160 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 497 | 0.150 |
Why?
| | Hemorrhage | 1 | 2025 | 809 | 0.150 |
Why?
| | Cholesterol, LDL | 5 | 2022 | 358 | 0.150 |
Why?
| | Thrombosis | 5 | 2024 | 393 | 0.150 |
Why?
| | Genomic Instability | 1 | 2020 | 66 | 0.150 |
Why?
| | Occipital Lobe | 1 | 2019 | 26 | 0.150 |
Why?
| | Homozygote | 3 | 2016 | 199 | 0.150 |
Why?
| | Mutation, Missense | 2 | 2023 | 340 | 0.150 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 3 | 2020 | 6 | 0.150 |
Why?
| | Th2 Cells | 4 | 2023 | 171 | 0.150 |
Why?
| | HLA-DRB1 Chains | 1 | 2020 | 109 | 0.150 |
Why?
| | Parietal Lobe | 1 | 2019 | 60 | 0.150 |
Why?
| | Eicosanoids | 2 | 2022 | 58 | 0.150 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 244 | 0.150 |
Why?
| | Diabetic Nephropathies | 1 | 2023 | 318 | 0.150 |
Why?
| | Photometry | 1 | 2019 | 3 | 0.150 |
Why?
| | Chromosomes, Human, Pair 12 | 4 | 2019 | 21 | 0.150 |
Why?
| | Genes, Mitochondrial | 1 | 2018 | 13 | 0.150 |
Why?
| | Sleep Medicine Specialty | 1 | 2019 | 10 | 0.150 |
Why?
| | Chromatography, Gas | 1 | 2019 | 32 | 0.150 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 46 | 0.150 |
Why?
| | Plasticizers | 1 | 2019 | 20 | 0.150 |
Why?
| | Receptors, Immunologic | 3 | 2022 | 206 | 0.140 |
Why?
| | Brazil | 6 | 2017 | 180 | 0.140 |
Why?
| | Temporal Lobe | 1 | 2019 | 104 | 0.140 |
Why?
| | Flame Retardants | 1 | 2019 | 16 | 0.140 |
Why?
| | Aged, 80 and over | 10 | 2025 | 8265 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 1053 | 0.140 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 8 | 0.140 |
Why?
| | Metabolism | 1 | 2018 | 44 | 0.140 |
Why?
| | India | 3 | 2009 | 218 | 0.140 |
Why?
| | Metabolomics | 2 | 2024 | 727 | 0.140 |
Why?
| | Databases, Genetic | 4 | 2021 | 248 | 0.140 |
Why?
| | Smad2 Protein | 1 | 2018 | 37 | 0.140 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 330 | 0.140 |
Why?
| | Brain | 2 | 2023 | 2933 | 0.140 |
Why?
| | Family | 4 | 2012 | 679 | 0.140 |
Why?
| | Sex Characteristics | 3 | 2014 | 790 | 0.140 |
Why?
| | Hominidae | 1 | 2019 | 87 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2018 | 32 | 0.140 |
Why?
| | Indians, North American | 2 | 2021 | 647 | 0.140 |
Why?
| | Exons | 3 | 2016 | 358 | 0.140 |
Why?
| | Frontal Lobe | 1 | 2019 | 160 | 0.140 |
Why?
| | Telomerase | 2 | 2024 | 248 | 0.140 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2010 | 87 | 0.140 |
Why?
| | Immunotherapy | 1 | 2022 | 653 | 0.130 |
Why?
| | Comorbidity | 1 | 2023 | 1658 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 432 | 0.130 |
Why?
| | Africa | 2 | 2020 | 116 | 0.130 |
Why?
| | Noncommunicable Diseases | 1 | 2017 | 19 | 0.130 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5868 | 0.130 |
Why?
| | Quality Control | 4 | 2021 | 163 | 0.130 |
Why?
| | Hyaluronoglucosaminidase | 1 | 2017 | 7 | 0.130 |
Why?
| | Organophosphates | 1 | 2019 | 187 | 0.130 |
Why?
| | Information Storage and Retrieval | 1 | 2018 | 121 | 0.130 |
Why?
| | Molecular Epidemiology | 3 | 2013 | 73 | 0.130 |
Why?
| | Animals | 20 | 2023 | 38058 | 0.130 |
Why?
| | Rural Health | 1 | 1997 | 87 | 0.130 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 22 | 0.130 |
Why?
| | Schistosoma mansoni | 1 | 2017 | 41 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 760 | 0.130 |
Why?
| | Endemic Diseases | 1 | 2017 | 33 | 0.130 |
Why?
| | Insulin Resistance | 1 | 2025 | 1241 | 0.130 |
Why?
| | Scavenger Receptors, Class B | 1 | 2016 | 14 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2020 | 547 | 0.120 |
Why?
| | Sequence Analysis, DNA | 6 | 2018 | 824 | 0.120 |
Why?
| | Cyclooxygenase 1 | 2 | 2014 | 26 | 0.120 |
Why?
| | DNA, Intergenic | 1 | 2016 | 29 | 0.120 |
Why?
| | Schistosomiasis | 1 | 2017 | 49 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 478 | 0.120 |
Why?
| | Carotid Artery Diseases | 1 | 2016 | 69 | 0.120 |
Why?
| | Enhancer Elements, Genetic | 1 | 2017 | 192 | 0.120 |
Why?
| | White Matter | 1 | 2018 | 153 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 653 | 0.120 |
Why?
| | Erythropoiesis | 1 | 2016 | 57 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 262 | 0.120 |
Why?
| | Immune System Diseases | 1 | 2016 | 39 | 0.120 |
Why?
| | Lipoprotein(a) | 1 | 2016 | 68 | 0.120 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 178 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 265 | 0.120 |
Why?
| | Kidney Transplantation | 2 | 2012 | 704 | 0.120 |
Why?
| | Anthropometry | 2 | 2022 | 200 | 0.120 |
Why?
| | Sexism | 1 | 2016 | 70 | 0.120 |
Why?
| | Myocardial Infarction | 2 | 2020 | 1209 | 0.120 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 573 | 0.120 |
Why?
| | Severity of Illness Index | 5 | 2019 | 2925 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2022 | 660 | 0.120 |
Why?
| | Genes, Modifier | 1 | 2015 | 2 | 0.110 |
Why?
| | Caveolin 2 | 1 | 2015 | 3 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2021 | 2050 | 0.110 |
Why?
| | CpG Islands | 3 | 2023 | 165 | 0.110 |
Why?
| | Factor VII | 1 | 2015 | 25 | 0.110 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 175 | 0.110 |
Why?
| | Molecular Sequence Annotation | 3 | 2021 | 105 | 0.110 |
Why?
| | United Kingdom | 3 | 2021 | 338 | 0.110 |
Why?
| | Receptors, Interferon | 1 | 2015 | 60 | 0.110 |
Why?
| | Collagen | 2 | 2015 | 456 | 0.110 |
Why?
| | Schistosomiasis japonica | 1 | 2015 | 34 | 0.110 |
Why?
| | Mutation Rate | 1 | 2015 | 30 | 0.110 |
Why?
| | Interleukin-10 | 2 | 2017 | 309 | 0.110 |
Why?
| | Minority Groups | 1 | 2017 | 282 | 0.110 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 162 | 0.110 |
Why?
| | Scleroderma, Systemic | 1 | 2016 | 123 | 0.110 |
Why?
| | Menopause | 2 | 2023 | 320 | 0.110 |
Why?
| | Mutant Chimeric Proteins | 1 | 2014 | 6 | 0.110 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2014 | 8 | 0.110 |
Why?
| | HLA-B27 Antigen | 1 | 2014 | 16 | 0.110 |
Why?
| | HMGA2 Protein | 1 | 2014 | 10 | 0.110 |
Why?
| | Chromosome Disorders | 1 | 2014 | 45 | 0.110 |
Why?
| | Hypertension | 2 | 2022 | 1263 | 0.110 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2014 | 26 | 0.110 |
Why?
| | Machine Learning | 3 | 2025 | 585 | 0.110 |
Why?
| | Cells, Cultured | 2 | 2021 | 4154 | 0.110 |
Why?
| | Rhinitis, Allergic | 1 | 2014 | 42 | 0.100 |
Why?
| | Family Health | 4 | 2011 | 191 | 0.100 |
Why?
| | Tobacco Use Disorder | 2 | 2013 | 218 | 0.100 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.100 |
Why?
| | beta-Defensins | 1 | 2013 | 22 | 0.100 |
Why?
| | Cystic Fibrosis | 2 | 2015 | 1158 | 0.100 |
Why?
| | Family Practice | 1 | 1997 | 404 | 0.100 |
Why?
| | Body Mass Index | 5 | 2022 | 2438 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 290 | 0.100 |
Why?
| | Obesity | 2 | 2022 | 3077 | 0.100 |
Why?
| | Exercise | 1 | 2025 | 2201 | 0.100 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 356 | 0.100 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 1993 | 14 | 0.100 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2017 | 576 | 0.100 |
Why?
| | Professional Impairment | 1 | 1993 | 3 | 0.100 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2011 | 78 | 0.100 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 89 | 0.100 |
Why?
| | Virginia | 2 | 2005 | 55 | 0.100 |
Why?
| | Longitudinal Studies | 5 | 2021 | 2947 | 0.100 |
Why?
| | Genetic Markers | 5 | 2016 | 331 | 0.100 |
Why?
| | Dentists | 1 | 1993 | 21 | 0.100 |
Why?
| | Stroke | 1 | 2022 | 1256 | 0.100 |
Why?
| | HEK293 Cells | 3 | 2021 | 744 | 0.100 |
Why?
| | Skin Tests | 4 | 2017 | 94 | 0.090 |
Why?
| | K562 Cells | 2 | 2024 | 93 | 0.090 |
Why?
| | Principal Component Analysis | 2 | 2010 | 197 | 0.090 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2012 | 9 | 0.090 |
Why?
| | Parents | 3 | 2007 | 1403 | 0.090 |
Why?
| | Ankyrins | 1 | 2012 | 12 | 0.090 |
Why?
| | Kallikreins | 1 | 2012 | 25 | 0.090 |
Why?
| | Duffy Blood-Group System | 2 | 2011 | 5 | 0.090 |
Why?
| | Critical Care | 1 | 2019 | 695 | 0.090 |
Why?
| | Fatty Acids | 1 | 2015 | 450 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2017 | 748 | 0.090 |
Why?
| | Microbiota | 1 | 2020 | 781 | 0.090 |
Why?
| | Triglycerides | 3 | 2015 | 520 | 0.090 |
Why?
| | Respiratory Sounds | 1 | 2012 | 105 | 0.090 |
Why?
| | Hepatitis B | 1 | 1993 | 66 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 1997 | 557 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2011 | 316 | 0.090 |
Why?
| | Phylogeny | 1 | 2016 | 1016 | 0.090 |
Why?
| | Mitochondria | 1 | 2018 | 984 | 0.090 |
Why?
| | Dioxygenases | 2 | 2023 | 36 | 0.090 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 161 | 0.090 |
Why?
| | Steroids | 1 | 2012 | 160 | 0.090 |
Why?
| | Heterozygote | 3 | 2021 | 315 | 0.090 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 14 | 0.080 |
Why?
| | Insulin | 4 | 2022 | 2507 | 0.080 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 36 | 0.080 |
Why?
| | Microtubule-Associated Proteins | 1 | 2012 | 196 | 0.080 |
Why?
| | Aquaporin 5 | 1 | 2010 | 3 | 0.080 |
Why?
| | Patients | 1 | 1993 | 180 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1782 | 0.080 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3409 | 0.080 |
Why?
| | Disease Progression | 5 | 2019 | 2847 | 0.080 |
Why?
| | Heredity | 2 | 2021 | 12 | 0.080 |
Why?
| | Chromosomes | 1 | 2011 | 108 | 0.080 |
Why?
| | Mice | 11 | 2023 | 18339 | 0.080 |
Why?
| | Cockroaches | 1 | 2010 | 22 | 0.080 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2010 | 28 | 0.080 |
Why?
| | Recombination, Genetic | 1 | 2011 | 205 | 0.080 |
Why?
| | Death Domain Receptor Signaling Adaptor Proteins | 1 | 2009 | 2 | 0.080 |
Why?
| | Curriculum | 1 | 1997 | 1059 | 0.080 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2010 | 37 | 0.080 |
Why?
| | Eosinophils | 2 | 2025 | 316 | 0.080 |
Why?
| | Lectins | 1 | 2010 | 44 | 0.080 |
Why?
| | Incidence | 4 | 2019 | 2879 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2011 | 285 | 0.080 |
Why?
| | Nuclear Family | 2 | 2007 | 52 | 0.080 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2009 | 64 | 0.080 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2009 | 74 | 0.080 |
Why?
| | Isoenzymes | 1 | 2010 | 299 | 0.080 |
Why?
| | Interviews as Topic | 2 | 2006 | 901 | 0.080 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2009 | 15 | 0.070 |
Why?
| | Chromosomes, Human | 1 | 2009 | 41 | 0.070 |
Why?
| | Tryptophan | 1 | 2010 | 181 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 197 | 0.070 |
Why?
| | Arginine | 1 | 2010 | 262 | 0.070 |
Why?
| | Caribbean Region | 4 | 2011 | 30 | 0.070 |
Why?
| | Confidence Intervals | 2 | 2014 | 333 | 0.070 |
Why?
| | Receptors, Leptin | 1 | 2009 | 25 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3863 | 0.070 |
Why?
| | Graft Rejection | 1 | 2012 | 540 | 0.070 |
Why?
| | Renal Dialysis | 1 | 1993 | 462 | 0.070 |
Why?
| | Agammaglobulinemia | 1 | 1989 | 36 | 0.070 |
Why?
| | Regression Analysis | 3 | 2025 | 1003 | 0.070 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 57 | 0.070 |
Why?
| | Nephrotic Syndrome | 1 | 1989 | 44 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2022 | 381 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1098 | 0.070 |
Why?
| | Genotyping Techniques | 2 | 2019 | 69 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 2 | 2023 | 623 | 0.070 |
Why?
| | Thromboxane B2 | 3 | 2018 | 23 | 0.070 |
Why?
| | Proteoglycans | 1 | 2009 | 110 | 0.070 |
Why?
| | Cholesterol | 2 | 2015 | 406 | 0.070 |
Why?
| | Siblings | 2 | 2011 | 195 | 0.070 |
Why?
| | Alcoholism | 3 | 2005 | 817 | 0.070 |
Why?
| | Chromosomes, Human, Pair 17 | 3 | 2019 | 55 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1054 | 0.070 |
Why?
| | Research Design | 2 | 2019 | 1135 | 0.070 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2007 | 19 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 846 | 0.060 |
Why?
| | British Columbia | 3 | 1997 | 23 | 0.060 |
Why?
| | Age of Onset | 3 | 2013 | 551 | 0.060 |
Why?
| | Cognition | 1 | 2015 | 1266 | 0.060 |
Why?
| | Inheritance Patterns | 1 | 2006 | 44 | 0.060 |
Why?
| | Antigens, CD | 1 | 2010 | 555 | 0.060 |
Why?
| | Thrombophilia | 1 | 2007 | 88 | 0.060 |
Why?
| | Databases, Factual | 1 | 2012 | 1486 | 0.060 |
Why?
| | Deoxyribonuclease HindIII | 1 | 2006 | 2 | 0.060 |
Why?
| | Infant, Newborn | 6 | 2012 | 6429 | 0.060 |
Why?
| | alpha-Linolenic Acid | 2 | 2017 | 8 | 0.060 |
Why?
| | Meta-Analysis as Topic | 3 | 2012 | 174 | 0.060 |
Why?
| | Europe | 2 | 2020 | 412 | 0.060 |
Why?
| | Adenosine Diphosphate | 2 | 2017 | 84 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2022 | 442 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 2 | 2019 | 24 | 0.060 |
Why?
| | Platelet Count | 2 | 2016 | 96 | 0.060 |
Why?
| | Registries | 1 | 2014 | 2385 | 0.060 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 406 | 0.060 |
Why?
| | Prospective Studies | 5 | 2020 | 7990 | 0.060 |
Why?
| | Epinephrine | 2 | 2017 | 155 | 0.060 |
Why?
| | Glucose | 2 | 2022 | 1047 | 0.060 |
Why?
| | Transfection | 3 | 2016 | 940 | 0.060 |
Why?
| | Ozone | 1 | 2006 | 132 | 0.050 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 57 | 0.050 |
Why?
| | Receptors, Prostaglandin | 1 | 2004 | 21 | 0.050 |
Why?
| | Complement C3 | 1 | 2006 | 191 | 0.050 |
Why?
| | Mucins | 1 | 2005 | 76 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2005 | 160 | 0.050 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2024 | 28 | 0.050 |
Why?
| | Janus Kinase 2 | 1 | 2024 | 29 | 0.050 |
Why?
| | Mites | 1 | 2004 | 8 | 0.050 |
Why?
| | Loss of Heterozygosity | 1 | 2024 | 52 | 0.050 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2024 | 25 | 0.050 |
Why?
| | Gene Targeting | 2 | 2020 | 82 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1980 | 0.050 |
Why?
| | Eye Proteins | 2 | 2021 | 90 | 0.050 |
Why?
| | Matched-Pair Analysis | 1 | 2003 | 37 | 0.050 |
Why?
| | Kidney | 2 | 2023 | 1495 | 0.050 |
Why?
| | Chromosomes, Human, Pair 14 | 2 | 2014 | 21 | 0.050 |
Why?
| | Adult Children | 1 | 2003 | 26 | 0.050 |
Why?
| | Time | 1 | 2003 | 86 | 0.050 |
Why?
| | Interleukin-6 | 2 | 2024 | 780 | 0.050 |
Why?
| | Epigenomics | 1 | 2024 | 114 | 0.050 |
Why?
| | Receptors, Complement | 1 | 2004 | 125 | 0.050 |
Why?
| | Guanine Nucleotide Dissociation Inhibitors | 1 | 2023 | 2 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2024 | 108 | 0.050 |
Why?
| | Societies, Medical | 2 | 2019 | 887 | 0.050 |
Why?
| | Genes | 1 | 2003 | 226 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4557 | 0.050 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 208 | 0.050 |
Why?
| | Eosinophilia | 2 | 2023 | 221 | 0.050 |
Why?
| | Sulfites | 1 | 2023 | 9 | 0.050 |
Why?
| | Environment | 2 | 2010 | 305 | 0.050 |
Why?
| | Sex Factors | 3 | 2014 | 2112 | 0.050 |
Why?
| | Aminopeptidases | 1 | 2023 | 21 | 0.050 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 496 | 0.050 |
Why?
| | Disease Susceptibility | 3 | 2014 | 348 | 0.050 |
Why?
| | Genes, Reporter | 2 | 2015 | 275 | 0.050 |
Why?
| | Cell Line | 3 | 2015 | 2882 | 0.050 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2022 | 15 | 0.050 |
Why?
| | Pruritus | 1 | 2023 | 59 | 0.050 |
Why?
| | Cooperative Behavior | 1 | 2005 | 465 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 170 | 0.050 |
Why?
| | Electroencephalography | 1 | 2005 | 532 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 134 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2016 | 2832 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 380 | 0.050 |
Why?
| | Fruit | 1 | 2023 | 152 | 0.050 |
Why?
| | Vegetables | 1 | 2023 | 170 | 0.050 |
Why?
| | Risk Assessment | 2 | 2025 | 3671 | 0.040 |
Why?
| | Colorado | 2 | 2024 | 4564 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2023 | 282 | 0.040 |
Why?
| | Age Factors | 3 | 2003 | 3333 | 0.040 |
Why?
| | Chromatin | 1 | 2025 | 561 | 0.040 |
Why?
| | RGS Proteins | 1 | 2021 | 17 | 0.040 |
Why?
| | Internationality | 2 | 2013 | 156 | 0.040 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 26 | 0.040 |
Why?
| | INDEL Mutation | 1 | 2021 | 19 | 0.040 |
Why?
| | Antigens, Protozoan | 1 | 2001 | 32 | 0.040 |
Why?
| | Colombia | 2 | 2013 | 42 | 0.040 |
Why?
| | Antibodies, Protozoan | 1 | 2001 | 41 | 0.040 |
Why?
| | Postmenopause | 1 | 2023 | 391 | 0.040 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2021 | 32 | 0.040 |
Why?
| | alpha Karyopherins | 1 | 2020 | 11 | 0.040 |
Why?
| | Receptors, LDL | 1 | 2020 | 53 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 2000 | 13 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 93 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2021 | 122 | 0.040 |
Why?
| | Lymphocytosis | 1 | 2000 | 11 | 0.040 |
Why?
| | Sepsis | 1 | 2007 | 640 | 0.040 |
Why?
| | Cricetinae | 1 | 2001 | 303 | 0.040 |
Why?
| | Tripartite Motif Proteins | 1 | 2020 | 40 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 153 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 123 | 0.040 |
Why?
| | Lod Score | 3 | 2009 | 62 | 0.040 |
Why?
| | Population Density | 1 | 2021 | 101 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 83 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2020 | 53 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 4282 | 0.040 |
Why?
| | Eating | 1 | 2023 | 389 | 0.040 |
Why?
| | Names | 1 | 2000 | 15 | 0.040 |
Why?
| | Pneumonia | 1 | 2006 | 631 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 547 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2006 | 846 | 0.040 |
Why?
| | Lens, Crystalline | 1 | 2001 | 136 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2020 | 26 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 93 | 0.040 |
Why?
| | Mutagenesis | 1 | 2021 | 192 | 0.040 |
Why?
| | Mucin-5B | 1 | 2022 | 234 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 205 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 75 | 0.040 |
Why?
| | North America | 2 | 2011 | 310 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2023 | 437 | 0.040 |
Why?
| | Fibrinolysis | 1 | 2021 | 162 | 0.040 |
Why?
| | Siberia | 1 | 2019 | 7 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 7173 | 0.040 |
Why?
| | Body Weight | 1 | 2003 | 976 | 0.040 |
Why?
| | Emigration and Immigration | 1 | 2000 | 66 | 0.040 |
Why?
| | Information Dissemination | 1 | 2021 | 223 | 0.040 |
Why?
| | Recombinases | 1 | 2019 | 8 | 0.040 |
Why?
| | Up-Regulation | 2 | 2016 | 851 | 0.040 |
Why?
| | Flame Ionization | 1 | 2019 | 2 | 0.040 |
Why?
| | Cloud Computing | 1 | 2019 | 6 | 0.040 |
Why?
| | Event-Related Potentials, P300 | 1 | 1999 | 15 | 0.040 |
Why?
| | Linear Models | 2 | 2017 | 854 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2018 | 37 | 0.040 |
Why?
| | Monoamine Oxidase | 1 | 1999 | 25 | 0.040 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2019 | 38 | 0.040 |
Why?
| | Cataract | 1 | 2001 | 238 | 0.040 |
Why?
| | Antibodies, Viral | 2 | 2000 | 672 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 1325 | 0.040 |
Why?
| | Limit of Detection | 1 | 2019 | 97 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 628 | 0.040 |
Why?
| | RNA Splicing Factors | 1 | 2019 | 64 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 151 | 0.030 |
Why?
| | Prevalence | 2 | 2016 | 2834 | 0.030 |
Why?
| | Reference Standards | 1 | 2019 | 177 | 0.030 |
Why?
| | Organ Size | 1 | 2019 | 463 | 0.030 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2018 | 10 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2019 | 574 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 2527 | 0.030 |
Why?
| | Virus Diseases | 1 | 2000 | 216 | 0.030 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2017 | 25 | 0.030 |
Why?
| | Skin | 1 | 2023 | 755 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2024 | 869 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2020 | 2029 | 0.030 |
Why?
| | Histone Code | 1 | 2017 | 38 | 0.030 |
Why?
| | Rubella Vaccine | 1 | 1997 | 6 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 459 | 0.030 |
Why?
| | HIV Infections | 1 | 1993 | 3154 | 0.030 |
Why?
| | Apolipoprotein E2 | 1 | 2016 | 3 | 0.030 |
Why?
| | Adipocytes | 1 | 2018 | 223 | 0.030 |
Why?
| | Rubella | 1 | 1997 | 22 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 948 | 0.030 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 13 | 0.030 |
Why?
| | Selection, Genetic | 1 | 2019 | 256 | 0.030 |
Why?
| | Interleukin-33 | 1 | 2017 | 45 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2017 | 80 | 0.030 |
Why?
| | Preceptorship | 1 | 1997 | 67 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1982 | 0.030 |
Why?
| | Demography | 1 | 2017 | 288 | 0.030 |
Why?
| | Denmark | 1 | 2016 | 50 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 184 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 521 | 0.030 |
Why?
| | Mean Platelet Volume | 1 | 2016 | 3 | 0.030 |
Why?
| | Data Accuracy | 1 | 2017 | 65 | 0.030 |
Why?
| | Allelic Imbalance | 1 | 2016 | 9 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2019 | 247 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 33 | 0.030 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 75 | 0.030 |
Why?
| | Neoplasms | 1 | 2012 | 2875 | 0.030 |
Why?
| | Massachusetts | 1 | 2017 | 180 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2016 | 54 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5408 | 0.030 |
Why?
| | Hematocrit | 1 | 2016 | 108 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 102 | 0.030 |
Why?
| | China | 1 | 2017 | 269 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1886 | 0.030 |
Why?
| | DNA | 1 | 2023 | 1463 | 0.030 |
Why?
| | Stearic Acids | 1 | 2015 | 16 | 0.030 |
Why?
| | Sarcoglycans | 1 | 2015 | 5 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 304 | 0.030 |
Why?
| | Bias | 1 | 2016 | 202 | 0.030 |
Why?
| | Lung Volume Measurements | 1 | 2015 | 46 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1539 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2016 | 145 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 441 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2015 | 68 | 0.030 |
Why?
| | Vascular Calcification | 1 | 2016 | 110 | 0.030 |
Why?
| | HTLV-I Infections | 1 | 1995 | 28 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 31 | 0.030 |
Why?
| | Social Class | 1 | 2017 | 268 | 0.030 |
Why?
| | Nutritional Status | 1 | 2017 | 354 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 341 | 0.030 |
Why?
| | Mice, Knockout | 3 | 2009 | 3121 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 323 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2017 | 344 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2014 | 37 | 0.030 |
Why?
| | Potassium Channels | 1 | 2015 | 145 | 0.030 |
Why?
| | Pneumothorax | 1 | 2014 | 51 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2015 | 112 | 0.030 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 88 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 548 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2027 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2015 | 185 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 905 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2018 | 439 | 0.030 |
Why?
| | Hemoglobins | 1 | 2016 | 384 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 400 | 0.030 |
Why?
| | Diet, Western | 1 | 2014 | 86 | 0.030 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 102 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2022 | 1152 | 0.020 |
Why?
| | Deferoxamine | 1 | 1993 | 25 | 0.020 |
Why?
| | Jamaica | 1 | 2013 | 8 | 0.020 |
Why?
| | Cotinine | 1 | 2013 | 79 | 0.020 |
Why?
| | District of Columbia | 1 | 2013 | 36 | 0.020 |
Why?
| | Societies, Dental | 1 | 1993 | 2 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 187 | 0.020 |
Why?
| | Aluminum | 1 | 1993 | 43 | 0.020 |
Why?
| | Gene Order | 1 | 2012 | 27 | 0.020 |
Why?
| | Educational Status | 1 | 2015 | 467 | 0.020 |
Why?
| | New York | 1 | 2013 | 125 | 0.020 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2012 | 19 | 0.020 |
Why?
| | Dynactin Complex | 1 | 2012 | 5 | 0.020 |
Why?
| | Parathyroid Hormone | 1 | 1993 | 112 | 0.020 |
Why?
| | Immunity, Mucosal | 1 | 2013 | 98 | 0.020 |
Why?
| | Organizational Policy | 1 | 1993 | 76 | 0.020 |
Why?
| | Untranslated Regions | 1 | 2012 | 3 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 6048 | 0.020 |
Why?
| | Adolescent Development | 1 | 2012 | 72 | 0.020 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 427 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 965 | 0.020 |
Why?
| | Wales | 1 | 2011 | 26 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 41 | 0.020 |
Why?
| | England | 1 | 2011 | 111 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2011 | 89 | 0.020 |
Why?
| | Eicosapentaenoic Acid | 1 | 2011 | 36 | 0.020 |
Why?
| | Canada | 1 | 2012 | 428 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2014 | 509 | 0.020 |
Why?
| | Luciferases | 1 | 2011 | 152 | 0.020 |
Why?
| | X Chromosome Inactivation | 1 | 2011 | 27 | 0.020 |
Why?
| | Microsatellite Repeats | 2 | 2003 | 157 | 0.020 |
Why?
| | Biological Evolution | 1 | 2015 | 488 | 0.020 |
Why?
| | Costa Rica | 1 | 2010 | 18 | 0.020 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 395 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1813 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2015 | 737 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 20 | 0.020 |
Why?
| | Artifacts | 1 | 2011 | 139 | 0.020 |
Why?
| | Overweight | 1 | 2015 | 609 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 403 | 0.020 |
Why?
| | Codon, Nonsense | 1 | 2010 | 44 | 0.020 |
Why?
| | Iron | 1 | 1993 | 359 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 386 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 135 | 0.020 |
Why?
| | Bone and Bones | 1 | 1993 | 314 | 0.020 |
Why?
| | Introns | 1 | 2011 | 254 | 0.020 |
Why?
| | Albuterol | 1 | 2010 | 73 | 0.020 |
Why?
| | Markov Chains | 1 | 2010 | 129 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1306 | 0.020 |
Why?
| | Kainic Acid | 1 | 2009 | 33 | 0.020 |
Why?
| | Biopsy | 1 | 1993 | 1075 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2010 | 246 | 0.020 |
Why?
| | Urban Population | 1 | 2012 | 491 | 0.020 |
Why?
| | Waist Circumference | 1 | 2010 | 139 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2009 | 42 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 331 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 379 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1030 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2010 | 182 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 251 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2009 | 163 | 0.020 |
Why?
| | Disease | 1 | 2009 | 98 | 0.020 |
Why?
| | Hospitals | 1 | 1993 | 730 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 231 | 0.020 |
Why?
| | Korea | 1 | 2007 | 18 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1985 | 0.020 |
Why?
| | beta-Thromboglobulin | 1 | 2007 | 3 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 3185 | 0.020 |
Why?
| | Binding Sites | 1 | 2010 | 1329 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2010 | 499 | 0.020 |
Why?
| | Drug Resistance | 1 | 2007 | 153 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1741 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2009 | 582 | 0.010 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 31 | 0.010 |
Why?
| | Genetic Testing | 2 | 1999 | 478 | 0.010 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 42 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2005 | 121 | 0.010 |
Why?
| | Hepatitis A Antibodies | 1 | 2005 | 3 | 0.010 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2005 | 41 | 0.010 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2005 | 29 | 0.010 |
Why?
| | Hepatitis A | 1 | 2005 | 25 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2004 | 26 | 0.010 |
Why?
| | Receptors, Virus | 1 | 2005 | 96 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 2005 | 172 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2009 | 1716 | 0.010 |
Why?
| | Antigens, Dermatophagoides | 1 | 2004 | 10 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 27 | 0.010 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2004 | 17 | 0.010 |
Why?
| | Gene Deletion | 1 | 2006 | 389 | 0.010 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 148 | 0.010 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2004 | 35 | 0.010 |
Why?
| | Germany | 1 | 2004 | 138 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2004 | 152 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 11679 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2006 | 383 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2006 | 1253 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 375 | 0.010 |
Why?
| | Kinetics | 1 | 2006 | 1627 | 0.010 |
Why?
| | Aquaporins | 1 | 2001 | 8 | 0.010 |
Why?
| | Osmosis | 1 | 2001 | 20 | 0.010 |
Why?
| | Chimera | 1 | 2001 | 61 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2001 | 124 | 0.010 |
Why?
| | Optics and Photonics | 1 | 2001 | 41 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 168 | 0.010 |
Why?
| | Lasers | 1 | 2001 | 132 | 0.010 |
Why?
| | Western Australia | 1 | 2001 | 8 | 0.010 |
Why?
| | HIV-2 | 1 | 2000 | 18 | 0.010 |
Why?
| | Cost Control | 1 | 2000 | 37 | 0.010 |
Why?
| | Herpesvirus 6, Human | 1 | 2000 | 14 | 0.010 |
Why?
| | Toxoplasma | 1 | 2000 | 49 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2930 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2000 | 168 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 176 | 0.010 |
Why?
| | Expert Testimony | 1 | 1999 | 42 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 2000 | 284 | 0.010 |
Why?
| | Observer Variation | 1 | 1999 | 355 | 0.010 |
Why?
| | Lymphocytes | 1 | 2000 | 382 | 0.010 |
Why?
| | Water | 1 | 2001 | 469 | 0.010 |
Why?
| | Rubella virus | 1 | 1997 | 7 | 0.010 |
Why?
| | Rats | 1 | 2006 | 5597 | 0.010 |
Why?
| | Paresthesia | 1 | 1997 | 14 | 0.010 |
Why?
| | Muscular Diseases | 1 | 1997 | 108 | 0.010 |
Why?
| | Arthralgia | 1 | 1997 | 61 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1997 | 129 | 0.010 |
Why?
| | Arthritis | 1 | 1997 | 96 | 0.010 |
Why?
| | HIV-1 | 1 | 2000 | 896 | 0.010 |
Why?
| | Postpartum Period | 1 | 1997 | 365 | 0.010 |
Why?
| | Pain | 1 | 1997 | 779 | 0.010 |
Why?
| | Physicians | 1 | 1999 | 939 | 0.010 |
Why?
| | Vaccination | 1 | 1997 | 1423 | 0.000 |
Why?
|
|
Mathias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|